Clinical trials
1 active trial in Australia
Recruiting, about to start, or running now.
See every trial on ClinicalTrials.gov (opens in a new tab)
Updated
Reviewed by Chandani Patel
Australia Preeclampsia Diagnostics Market Industry Trends and Forecast to 2034: Segmented by (Test, Use, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$20.0 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $16.2 Mn | — | — |
| 2025 (base) | $17.6 Mn | +$1.4 Mn | — |
| 2026 (forecast) | $19.2 Mn | +$1.6 Mn | +8.8% |
| 2027 (forecast) | $20.9 Mn | +$1.7 Mn | +18.4% |
| 2028 (forecast) | $22.7 Mn | +$1.8 Mn | +28.8% |
| 2029 (forecast) | $24.7 Mn | +$2.0 Mn | +40.1% |
| 2030 (forecast) | $26.9 Mn | +$2.2 Mn | +52.5% |
| 2031 (forecast) | $29.3 Mn | +$2.4 Mn | +65.9% |
| 2032 (forecast) | $31.8 Mn | +$2.6 Mn | +80.5% |
| 2033 (forecast) | $34.6 Mn | +$2.8 Mn | +96.4% |
| 2034 (forecast) | $37.7 Mn | +$3.0 Mn | +113.6% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $17.6 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $37.7 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 8.8% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Test, use and end user (see all) |
| Key players | Roche Diagnostics, Thermo Fisher Scientific Inc., Perkin Elmer, Siemens Healthineers, Quidel Corporation (see all) |
| Regulator in Australia | TGASource: Therapeutic Goods Administration. Checked 14 Nov 2026. |
| Active clinical trials | 1 in AustraliaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Australia. Retrieved 12 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Preeclampsia diagnostics are blood tests and monitoring tools that predict or detect dangerous high blood pressure in pregnancy.
Key segments of the preeclampsia Diagnostics market include test (sFlt-1/PlGF Ratio Tests, PlGF Tests and Blood Pressure Monitoring) and use (Screening, Diagnosis and Prognosis).
Greater awareness of women's health needs, more funding for female-focused research, later pregnancies and an ageing female population are driving the preeclampsia Diagnostics market. New products designed around women's biology and digital care are improving access.
Femtech, personalised care and new treatments for under-served conditions open strong growth for the preeclampsia Diagnostics market, especially as employers and payers add women's health benefits.
Under-diagnosis, stigma around some conditions, limited insurance coverage and a long history of under-research in women's health hold back the preeclampsia Diagnostics market.
The preeclampsia Diagnostics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Medical devices must be included in the Australian Register of Therapeutic Goods (ARTG), run by the Therapeutic Goods Administration (TGA), before they can be supplied.[1] Medicare pays for public hospital care and many doctor visits, and the Pharmaceutical Benefits Scheme (PBS) subsidises listed medicines.[2] ClinicalTrials.gov lists 1 study on Preeclampsia Diagnostics that is recruiting, active or about to start in Australia.[3]
[1] Therapeutic Goods Administration. Checked 14 Nov 2026.
[2] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.
[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Australia. Retrieved 12 Nov 2026.
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how preeclampsia Diagnostics products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Australia.
What doctors and scientists are doing in Preeclampsia Diagnostics right now, from free public sources.
1 active trial in Australia
Recruiting, about to start, or running now.
See every trial on ClinicalTrials.gov (opens in a new tab)Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 15 Nov 2026.
[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 16 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 16 Nov 2026.
From our blog
Australia · 1 shared keyword
Australia
Australia
Australia
Australia
Australia
Digital Health · Australia
Healthcare Services · Australia
Healthcare Services · Australia
Pharmaceuticals · Australia
Healthcare Services · Australia
Healthcare Services · Australia